SCHEMBL3399580

SCHEMBL3399580

CNOC(=O)N1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD11B1 P28845 1/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29124849 1.00 ALDH1A1 (0.45) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL26614382 0.98 ALDH1A1 (0.42) ALDH1A1POLBSMN1; SMN2MEN1KMT2A
SCHEMBL25252973 0.93
SCHEMBL16512381 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL9987783 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL304391 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL3316653 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL14827284 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL12481132 0.78 ALDH1A1 (0.50) ALDH1A1POLBSMN1; SMN2KMT2AHSD11B1
SCHEMBL22667497 0.78 TPSAB1 (0.48) ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220408-A1 MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS Neumora Therapeutics, Inc. (US) 2023-11-16 WO disclosed
EP-4225749-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2023-08-16 EP disclosed
EP-4204411-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN Nalo Therapeutics (US) 2023-07-05 EP disclosed
WO-2023098656-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE, LTD. (GB) 2023-06-08 WO disclosed
EP-4157888-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS Cullgen (Shanghai), Inc. (CN) 2023-04-05 EP disclosed
WO-2022073469-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2022-04-14 WO disclosed
WO-2022046861-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN NALO THERAPEUTICS (US) 2022-03-03 WO disclosed
WO-2021239117-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI) , INC. (CN) 2021-12-02 WO disclosed
WO-2021058017-A1 DEGRADATION OF ANDROGEN RECEPTOR (AR) BY CONJUGATION OF AR ANTAGONISTS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2021-04-01 WO disclosed
EP-2247588-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-11-10 EP disclosed
WO-2009107850-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-03 WO disclosed
WO-2009072643-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-11 WO disclosed